Enzon Inc. (NASDAQ:ENZN) announced Thursday that it signed aworldwide licensing agreement with the National Institutes ofHealth, granting the Piscataway, N.J., company rights to arecombinant form of glucocerebrosidase for treating Gaucher'sdisease. Enzon will use its PEG technology to develop achemically modified form of the drug in an effort to extend itshalf-life in the circulation.

(c) 1997 American Health Consultants. All rights reserved.

No Comments